The trajectory of Sildenafil presents a complex case for stakeholders in the drug sector. While initially a phenomenal success, producing vast sums, the intellectual property lapse and the subsequent arrival of generic https://pharma863914.buyoutblog.com/41810037/the-little-copyright-and-big-pharma-a-speculative-play